Obesity and the Polycystic Ovary Syndrome

Medical Clinics of North America

Volumn 91, Issue 6, 2007, Pages 1151-1168

  Magnotti, Michael ^a   Futterweit, Walter ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANTIANDROGEN; DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORGESTIMATE; FINASTERIDE; GLUCOSE; INSULIN; METFORMIN; PIOGLITAZONE; RESISTIN; RIOMET; ROSIGLITAZONE; SPIRONOLACTONE; TRI CYCLEN; UNCLASSIFIED DRUG; YAZ;

ACANTHOSIS NIGRICANS; BODY FAT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEPRESSION; DISEASE ASSOCIATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EDEMA; ESTHETICS; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERKALEMIA; IMPAIRED GLUCOSE TOLERANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SELF ESTEEM; SIDE EFFECT; TERATOGENICITY; THROMBOEMBOLISM; WEIGHT GAIN; WEIGHT REDUCTION;

FEMALE; HUMANS; OBESITY; POLYCYSTIC OVARY SYNDROME; PREVALENCE; RISK FACTORS; WEIGHT GAIN;

EID: 35448929866     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2007.06.010     Document Type: Review

References (80)

1. Azziz R., Woods K.S., Reyna R., et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89 (2004) 2745-2749
2. Hart R., Hickey M., and Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 18 (2004) 671-683
3. Asuncion M., Calvo R.M., San Millan J.L., et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected caucasian women from Spain. J Clin Endocrinol Metab 85 (2000) 2434-2438
4. Franks S. Polycystic ovary syndrome. N Engl J Med 333 (1995) 853-861
5. Alvarez-Blasco F., Botella-Carretero J.I., San Milan J.L., et al. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med 166 (2006) 2081-2086
6. Pasquali R., Antenucci D., Casimirri F., et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 68 (1989) 173-179
7. Moran L.J., Brinkworth G., Noakes M., et al. Effects of lifestyle modification in polycystic ovarian syndrome. Reprod Biomed Online 12 (2006) 569-578
8. Moghetti F., Castello R., Negri C., et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 85 (2000) 139-146
9. Baillargeon J.P., Iuorno M.J., and Nestler J.E. Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol 46 (2003) 325-340
10. Kitzinger K., and Willmott J. "The thief of womanhood": women's experience of polycystic ovarian syndrome. Soc Sci Med 54 (2002) 349-361
11. Zawadsky J.K., Dunaif A., et al. Polycystic ovary syndrome. In: Dunaif A., Givens J.R., and Haseltine F.P. (Eds). Diagnostic criteria for polycystic ovary syndrome: towards a rational approach (1992), Blackwell Scientific Publications, Boston 377-384
12. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81 (2004) 19-25
13. Azziz R., Carmina E., Dewailly D., et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 91 (2006) 4237-4245
14. Azziz R., Sanchez L.A., Knochenhauer E.S., et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 89 (2004) 453-462
15. Carmina E., and Lobo R.A. Polycystic ovaries in hirsute women with normal menses. Am J Med 111 (2001) 602-606
16. Kahsar-Miller M.D., Nixon C., Boots L.R., et al. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril 75 (2001) 35-38
17. Yildiz B.O., Yarali H., Oguz H., et al. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 2031-2036
18. Sam S., Legro R.S., Essah P., et al. Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome. Proc Natl Acad Sci USA 103 (2006) 7030-7035
19. Escobar-Morreale H.F., Luque-Ramirez M., and San Millan J.L. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev 26 (2005) 251-282
20. Urbanek M., Woodroffe A., Ewens K.G., et al. Candidate gene region for polycystic ovary syndrome on chromosome 19p13.2. J Clin Endocrinol Metab 90 (2005) 6623-6629
21. Tucci S., Futterweit W., Concepcion E.S., et al. Evidence for association of polycystic ovary syndrome in caucasian women with a marker at the insulin receptor gene locus. J Clin Endocrinol Metab 86 (2001) 446-449
22. Futterweit W. Pathophysiology of polycystic ovarian syndrome. In: Redmond G.P. (Ed). Androgenic disorders (1995), Raven Press, New York 77-166
23. Polson D.W., Adams J., Wadsworth J., et al. Polycystic ovaries: a common finding in normal women. Lancet 1 (1988) 870-872
24. Michelmore K.E., Balen A.H., Douglas D.B., et al. Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol (Oxf) 51 (1999) 779-786
25. Futterweit W., Diamanti-Kandarakis E., and Azziz R. Clinical features of the polycystic ovary syndrome. In: Azziz R., Nestler J.E., and Dewailly D. (Eds). Androgen excess disorders in women: polycystic ovary syndrome and other disorders. 2nd edition (2006), Humana Press Inc., Totowa (NJ) 155-167
26. Ehrmann D.A. Polycystic ovary syndrome. N Engl J Med 352 (2005) 1223-1236
27. Balen A.H., Conway G.S., Kaltsas G., et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 10 (1995) 2107-2111
28. Yeh H.C., Futterweit W., and Thornton J.C. Polycystic ovarian disease: US features in 104 patients. Radiology 163 (1987) 11-16
29. van Hooff M.H., Voorhorst F.J., Kapstein M.B., et al. Predictive value of menstrual cycle pattern, body mass index, hormone levels and polycystic ovaries at age 15 years for oligo-amenorrhoea at age 18 years. Hum Reprod 19 (2004) 383-392
30. Legro R.S. The genetics of obesity: lessons for polycystic ovary syndrome. Ann N Y Acad Sci 900 (2000) 193-202
31. Carmina E., Legro R.S., Stamets K., et al. Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum Reprod 18 (2003) 2289-2293
32. Dunaif A., Segal K.R., Futterweit W., et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38 (1989) 1165-1174
33. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18 (1997) 774-800
34. Venkatesan A.M., Dunaif A., and Corbould A. Insulin resistance in polycystic ovary syndrome: progress and paradoxes. Recent Prog Horm Res 56 (2001) 295-308
35. Gambeneri A., Pelusi C., Vicennati V., et al. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 26 (2002) 883-889
36. Futterweit W., et al. An endocrine approach to obesity. In: Simopoulos A.P., VanItallie T.B., and Gullo S.P. (Eds). Obesity: new directions in assessment and management (1994), Charles Press, New York 96-121
37. Kiddy D.S., Hamilton-Fairley D., Bush A., et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 36 (1992) 105-111
38. Harborne L., Fleming R., Lyall H., et al. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 4116-4123
39. Jakubowicz D.J., and Nestler J.E. 17 alpha-hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome after dietary weight loss. J Clin Endocrinol Metab 82 (1997) 556-560
40. Boden G., and Shulman G.I. Free fatty acids in obesity and type 2 diabetes defining their role in the development of insulin resistance and b-cell dysfunction. Eur J Clin Invest 32 Suppl 3 (2002) 14-23
41. Vildirim B., Sadir N., and Kaleli B. Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome. Fertil Steril 79 (2003) 1358-1364
42. Carey D.G., Jenkins A.B., Campbell L.V., et al. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of IDDM. Diabetes 45 (1996) 633-638
43. DeNino W.F., Tchernof A., Dionne I.J., et al. Contribution of abdominal adiposity to age-related differences in insulin sensitivity and plasma lipids in healthy nonobese women. Diabetes Care 24 (2001) 925-932
44. Puder J.J., Varga S., Kraenzlin M., et al. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab 90 (2005) 6014-6021
45. Hermanns-Le T., Scheen A., and Pierard G.E. Acanthosis nigricans associated with insulin resistance: pathophysiology and management. Am J Clin Dermatol 5 (2004) 199-203
46. Dunaif A., Green G., Phelps R.G., et al. Acanthosis nigricans, insulin action, and hyperandrogenism: clinical, histological and biochemical findings. J Clin Endocrinol Metab 73 (1991) 590-595
47. Glueck C.J., Papanna R., Wang P., et al. Incidence and treatment of the metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 52 (2003) 908-915
48. Coviello A.D., Legro R.S., and Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increased androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 91 (2006) 492-497
49. Apridonidze T., Essah P.A., Iuorno M.J., et al. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol 90 (2005) 1929-1935
50. Cobin R.H., Futterweit W., Nestler J.E., et al. American association of clinical endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. Polycystic Ovary Writing Committee. Endocr Pract 11 (2005) 125-134
51. Nestler J.E. Insulin resistance syndrome and polycystic ovary syndrome. Endocr Pract 9 Suppl 2 (2003) 86-89
52. Diamanti-Kandarakis E., Kouli C., Alexandraki K., et al. Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004) 1273-1276
53. Ehrmann D.A., Barnes R.B., Rosenfeld R.L., et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22 (1999) 141-146
54. Legro R.S., Kunselman A.R., Dodson W.C., et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 264 affected women. J Clin Endocrinol Metab 84 (1999) 165-169
55. Tominaga M., Eguchi H., Manaka H., et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22 (1999) 920-924
56. Norman R.J., Masters L., Milner C.R., et al. Relative risk of conversion from normoglycemia to impaired glucose tolerance of non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 16 (2001) 1995-1998
57. Golland I.M., Vaughan Williams C.A., Shalet S.M., et al. Lack of predictive value of HbA1C for impaired glucose tolerance in polycystic ovary syndrome. Gynecol Endocrinol 3 (1989) 229-235
58. Legro R.S., Gnatuk C.L., Kunselman A.R., et al. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 90 (2005) 3236-3242
59. Peppard H.R., Marfori J., Iuorno M.J., et al. Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes mellitus. Diabetes Care 24 (2001) 1050-1052
60. Conn J.J., Jacobs H.S., and Conway G.S. The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clin Endocrinol (Oxf) 52 (2000) 81-86
61. Considine R.V., Sinha M.K., Heiman M.L., et al. Serum immunoreactive-leptin concentrations in normal weight and obese humans. N Engl J Med 334 (1996) 292-295
62. Havel P.J., Kasim-Karakas S., Dubuc G.R., et al. Gender differences in plasma leptin concentrations. Nat Med 2 (1996) 949-950
63. Heymsfield S.B., Greenberg A.S., Fujioka K., et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 283 (1999) 1567-1568
64. Matsuzawa Y., Funahashi T., Kihara S., et al. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24 (2004) 29-33
65. Koerner A., Kratzsch J., and Kiess W. Adipocytokines: leptin-the classical, resistin-the controversial, adiponectin-the promising, and more to come. Best Pract Res Clin Endocrinol Metab 19 (2005) 525-546
66. Yamamoto Y., Hirose H., Saito I., et al. Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. J Clin Endocrinol Metab 89 (2004) 87-90
67. Rea R., and Donnelly R. Resistin: an adipocyte-derived hormone. Has it a role in diabetes and obesity?. Diabetes Obes Metab 6 (2004) 163-170
68. Escobar-Morreale H.F., Villuendas G., Botella-Carretero J.I., et al. Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study. Hum Reprod 21 (2006) 2257-2265
69. Glintborg D., Andersen M., Hagen C., et al. Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. Eur J Endocrinol 155 (2006) 337-345
70. Carmina E., Orio F., Palomba S., et al. Evidence for altered adipocyte function in polycystic ovary syndrome. Eur J Endocrinol 152 (2005) 389-394
71. Skommer J., Katulski K., Poreba E., et al. Gherlin expression in women with polycystic ovary syndrome: a preliminary study. Eur J Gynaecol Oncol 26 (2005) 553-556
72. Neveu N., Granger L., St-Michel P., et al. Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with polycystic ovary syndrome. Fertil Steril 87 (2007) 113-120
73. Liu K.E., Tataryn I.V., and Sagle M. Use of metformin for ovulation induction in women who have polycystic ovary syndrome with or without evidence of insulin resistance. J Obstet Gynaecol Can 28 (2006) 595-599
74. Siebert T.I., Kruger T.F., Steyn D.W., et al. Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review. Fertil Steril 86 (2006) 1432-1437
75. Homburg R. Pregnancy complications in PCOS. Best Pract Res Clin Endocrinol Metab 20 (2006) 281-292
76. Khattab S., Mohsen I.A., Foutouh I.A., et al. Metformin reduces abortion in pregnant women with polycystic ovary syndrome. Gynecol Endocrinol 22 (2006) 680-684
77. Guido M., Romualdi D., Giuliani M., et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 89 (2004) 2817-2823
78. Batukan C., and Muderris I.I. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil Steril 85 (2006) 436-440
79. Shulman L.P. Oral contraceptives: risks. Obstet Gynecol Clin North Am 27 (2000) 695-704
80. Azziz R. The evaluation and management of hirsutism. Obstet Gynecol 101 (2003) 995-1007